Bird Rock Bio

9 articles about Bird Rock Bio

• Bird Rock Bio Files IND Application for Phase 2 Study of Nimacimab for Treatment of Renal Diseases

  5/28/2020

  Bird Rock Bio, Inc.,  a clinical stage biopharmaceutical company, announced today that the Company has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a phase 2 clinical study of nimacimab, also known as RYI-018, in patients with one of the following renal dis

• Bird Rock Bio Announces Successful Completion of Phase 1B Safety Study and Readiness for Phase 2B Study of Nimacimab in Patients with Diabetic Kidney Disease

  10/17/2019

  Nimacimab is a first-in-class negative-allosteric modulating antibody agonist to the cannabinoid 1 (CB1) receptor.

• Bird Rock Bio Completes Clinical Trial of Nimacimab in Patients with Fatty Liver Disease

  9/13/2018

  Nimacimab, also known as RYI-018 or JNJ-2463, is a negative-allosteric modulating antibody targeting the cannabinoid 1 recepto

• Retrophin Announces Appointment of Casey Logan as Vice President of Corporate Development

  3/5/2018

  Retrophin, Inc. (NASDAQ:RTRX) today announced that Casey Logan has joined the Company as vice president, corporate development.

• Bird Rock Bio Completes Single Ascending Dose Human Clinical Trial For Namacizumab; Generates Safety, Tolerability, And Pharmacokinetics Data; Prepares To Initiate Study In Non-Alcoholic Fatty Liver Disease Patients

  6/5/2017

• Bird Rock Bio Release: Biopharma Receives Approval To Start First In Human Clinical Trial For Namacizumab, Enters Into Agreement With GE Healthcare For Process Development And Scale-Up To Provide Clinical Phase 2 Cgmp Material, And Enters Into A Collabora

  1/11/2017

• Bird Rock Bio Receives Approval From ANVISA And CONEP To Initiate The First Phase 2 Study In Brazil Of Gerilimzumab For Rheumatoid Arthritis

  1/3/2017

• Bird Rock Bio Submits Clinical Trial Authorization For The First In Human Clinical Trial For Namacizumab

  10/27/2016

• Bird Rock Bio's Gerilimzumab, An Anti-IL-6 Antibody, Demonstrates Potential For Affordable Global Access To A Novel Biologic To Treat Rheumatoid Arthritis

  3/16/2016